DIA Biosimilars 2013

Immune Design

Regulus Therapeutics appoints Bruce Carter to board of directors

Wednesday, May 2, 2012 04:38 PM

Regulus Therapeutics, a biopharmaceutical company focused on medicines targeting microRNAs, has appointed Bruce Carter, Ph.D., to its board of directors.

More... »

Cenduit: Now with Patient Reminders

Immune Design, Sanofi collaborate in allergy research

Wednesday, October 26, 2011 10:39 AM

Immune Design has entered into an early-stage research collaboration with Sanofi-Aventis to investigate the use of IDC's Glucopyranosyl Lipid Adjuvant (GLA) technology, a toll–like receptor 4 (TLR-4) agonist, in the field of allergy.

More... »

CRF Health – eCOA Forum

Immune Design adds Carlos Paya as CEO

Wednesday, April 27, 2011 01:22 PM

Seattle-based vaccine developer Immune Design’s new CEO is Carlos Paya, the former president of Ireland-based biotech Elan. Paya is replacing Immune Design’s founding CEO, Steve Reed, who will continue to serve on the company’s executive management team and board, according to Xconomy Seattle.

More... »

CenterWatch Drugs in Clinical Trials Database Library. Drug intelligence right at your fingertips.
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs